Published in Mol Cancer Ther on March 01, 2007
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Aurora A kinase activity influences calcium signaling in kidney cells. J Cell Biol (2011) 1.10
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 1.01
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res (2010) 0.96
Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. J Mol Signal (2010) 0.84
c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PLoS One (2014) 0.79
The RAS-Effector Interaction as a Drug Target. Cancer Res (2017) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 22.23
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
Transformation of mammalian cells by constitutively active MAP kinase kinase. Science (1994) 8.69
MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science (2002) 6.29
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature (1998) 5.24
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell (2003) 3.42
Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol Cell Biol (1989) 2.90
Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer (2001) 2.82
The dark side of Ras: regulation of apoptosis. Oncogene (2003) 2.60
Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol (2004) 1.62
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res (1997) 1.56
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A (2004) 1.52
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci U S A (2002) 1.52
Biological assays for cellular transformation. Methods Enzymol (1994) 1.51
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res (1996) 1.48
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res (2004) 1.46
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther (2005) 1.46
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene (1994) 1.44
Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem (2001) 1.40
Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets (2003) 1.37
Paclitaxel in cancer therapy. Expert Opin Pharmacother (2002) 1.26
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer (2005) 1.22
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol (2006) 1.16
Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene (2002) 1.12
Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med (2005) 1.12
Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer (2002) 1.07
Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res (2003) 0.99
Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells. J Biol Chem (2000) 0.99
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther (2006) 0.99
Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis (2004) 0.97
Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res (2005) 0.96
Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother (2002) 0.96
Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br J Cancer (2000) 0.94
Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection. J Virol (2004) 0.89
Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens. Radiother Oncol (1998) 0.85
High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin Cancer Res (1998) 0.85
Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. Leukemia (2005) 0.84
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. Cancer Chemother Pharmacol (2003) 0.81
Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. Bioorg Med Chem Lett (2004) 0.81
Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells. Oncol Rep (2000) 0.80
Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer. BioDrugs (2006) 0.79
Cetuximab in the treatment of colorectal cancer. Future Oncol (2005) 0.78
Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. Cancer Lett (2003) 0.77
HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell (2007) 6.50
The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol (2005) 2.52
KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet (2002) 2.28
K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res (2007) 2.26
Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci (2012) 1.84
CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci (2009) 1.84
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64
Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle (2007) 1.55
Cell cycle-dependent ciliogenesis and cancer. Cancer Res (2008) 1.54
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci U S A (2002) 1.52
A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res (2007) 1.48
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A (2004) 1.42
Automated Greulich-Pyle bone age determination in children with chronic kidney disease. Pediatr Nephrol (2015) 1.39
Dissection of HEF1-dependent functions in motility and transcriptional regulation. J Cell Sci (2002) 1.29
Primary cilia and the cell cycle. Methods Cell Biol (2009) 1.28
Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem (2008) 1.27
HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle (2006) 1.25
Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant (2011) 1.24
Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle. Mol Biol Cell (2006) 1.19
Long term persistence of clonal malaria parasite Plasmodium falciparum lineages in the Colombian Pacific region. BMC Genet (2013) 1.14
Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis. Mol Biol Cell (2012) 1.13
Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J (2003) 1.12
The IKK-2/Ikappa Balpha /NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice. J Biol Chem (2001) 1.11
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Mol Cancer Ther (2007) 1.10
Aurora A kinase activity influences calcium signaling in kidney cells. J Cell Biol (2011) 1.10
Interdependence of cell attachment and cell cycle signaling. Curr Opin Cell Biol (2006) 1.08
A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell (2008) 1.07
Targeting EGFR resistance networks in head and neck cancer. Cell Signal (2009) 1.07
The GDP exchange factor AND-34 is expressed in B cells, associates with HEF1, and activates Cdc42. J Immunol (2003) 1.06
NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One (2011) 1.06
A novel RING finger protein, human enhancer of invasion 10, alters mitotic progression through regulation of cyclin B levels. Mol Cell Biol (2003) 1.06
The extracellular matrix and ciliary signaling. Curr Opin Cell Biol (2012) 1.03
The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci (2012) 0.99
Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res (2003) 0.99
Rapid calcium-dependent activation of Aurora-A kinase. Nat Commun (2010) 0.98
Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets (2009) 0.96
Detection of peptides, proteins, and drugs that selectively interact with protein targets. Genome Res (2002) 0.96
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res (2010) 0.96
Age-associated decline in resistance to Babesia microti is genetically determined. J Infect Dis (2004) 0.95
Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. Bioorg Med Chem Lett (2006) 0.95
Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit (2002) 0.95
Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol (2005) 0.94
Autoinhibited proteins as promising drug targets. J Cell Biochem (2004) 0.92
Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Expert Opin Ther Pat (2013) 0.91
Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov (2012) 0.90
Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Proc Natl Acad Sci U S A (2013) 0.90
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther (2010) 0.89
Human enhancer of invasion-cluster, a coiled-coil protein required for passage through mitosis. Mol Cell Biol (2004) 0.89
Aurora kinases in head and neck cancer. Lancet Oncol (2013) 0.89
Total synthesis of tubulysin U and V. Angew Chem Int Ed Engl (2006) 0.89
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res (2013) 0.88
Ras-driven transformation of human nestin-positive pancreatic epithelial cells. Methods Enzymol (2008) 0.87
Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol (2013) 0.87
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat (2011) 0.86
The centrosomal kinase Plk1 localizes to the transition zone of primary cilia and induces phosphorylation of nephrocystin-1. PLoS One (2012) 0.86
Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. J Mol Signal (2010) 0.84
Dcas supports cell polarization and cell-cell adhesion complexes in development. PLoS One (2010) 0.83
Structure, stability, and function of hDim1 investigated by NMR, circular dichroism, and mutational analysis. Biochemistry (2003) 0.83
Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem (2004) 0.82
Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol (2007) 0.82
A gene expression system offering multiple levels of regulation: the Dual Drug Control (DDC) system. BMC Biotechnol (2004) 0.82
Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling". Sci Signal (2012) 0.82
CAS proteins in health and disease: an update. IUBMB Life (2014) 0.82
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res (2013) 0.82
Babesia microti primarily invades mature erythrocytes in mice. Infect Immun (2006) 0.82
A pseudo-ligand approach to virtual screening. Comb Chem High Throughput Screen (2006) 0.81
Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. Bioorg Med Chem Lett (2004) 0.81
Automated compound classification using a chemical ontology. J Cheminform (2012) 0.80
Solitary cutaneous dendritic cell tumor in a child: role of dendritic cell markers for the diagnosis of skin Langerhans cell histiocytosis. J Am Acad Dermatol (2005) 0.80
NMR screening for lead compounds using tryptophan-mutated proteins. J Med Chem (2008) 0.80
Issues in interpreting the in vivo activity of Aurora-A. Expert Opin Ther Targets (2014) 0.80
Overproduction, purification, crystallization and preliminary X-ray diffraction studies of the human transcription repressor ERH. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.80
Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis. Int Urol Nephrol (2012) 0.79
On the industrial applications of MCRs: molecular diversity in drug discovery and generic drug synthesis. Mol Divers (2010) 0.79
Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett (2005) 0.78
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett (2005) 0.78
The role of ultrasound in detection and management of regional disease in melanoma patients. Semin Oncol (2002) 0.78
A ciliary timer for S-phase entry. Nat Rev Mol Cell Biol (2007) 0.78
Arterial and retinal vascular changes in hypertensive and prehypertensive adolescents. Am J Hypertens (2013) 0.78
Development of a yeast two-hybrid screen for selection of human Ras-Raf protein interaction inhibitors. Methods Mol Biol (2005) 0.78
Overproduction, purification, crystallization and preliminary X-ray diffraction studies of the human spliceosomal protein TXNL4B. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.78
Relocalization of endothelial cell beta-catenin after coculture with activated neutrophils from patients undergoing cardiac surgery with cardiopulmonary bypass. J Invest Surg (2004) 0.78
A combined yeast/bacteria two-hybrid system: development and evaluation. Mol Cell Proteomics (2005) 0.78
Rat growth plate chondrocytes express low levels of 25-hydroxy-1alpha-hydroxylase. J Steroid Biochem Mol Biol (2004) 0.76
Integrating in silico resources to map a signaling network. Methods Mol Biol (2014) 0.75
Combinatorial chemistry by ant colony optimization. Future Med Chem (2014) 0.75
A swollen face after dental surgery. J Dtsch Dermatol Ges (2005) 0.75
TACCing on new functions for the TSC2 tumor suppressor. Cell Cycle (2010) 0.75
Analysis and manipulation of intracellular signaling cascades. Methods (2004) 0.75
From correlation to causality: microarrays, cancer, and cancer treatment. Biotechniques (2003) 0.75
Micromoulded plastic components. Med Device Technol (2002) 0.75